AbbVie Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending December 30, 2020 was $618 Million (a -0.32% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses increased by 44.39%
  • Annual Non-operating Interest Expenses for 2020 was $2.28 Billion (a 51.09% increase from previous year)
  • Annual Non-operating Interest Expenses for 2019 was $1.51 Billion (a 31.91% increase from previous year)
  • Annual Non-operating Interest Expenses for 2018 was $1.14 Billion (a 13.94% increase from previous year)
  • Twelve month Non-operating Interest Expenses ending December 30, 2020 was $2.28 Billion (a 7.7% increase compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses increased by 41.44% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$2.28 Billion $2.12 Billion $1.92 Billion $1.61 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of AbbVie Inc.

Most recent Non-operating Interest Expensesof ABBV including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of AbbVie Inc.

AbbVie Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $618.0 $620.0 $614.0 $428.0 $2,280.0
2019 $455.0 $420.0 $309.0 $325.0 $1,509.0
2018 $319.0 $302.0 $272.0 $251.0 $1,144.0
2017 $252.0 $252.0 $253.0 $247.0 $1,004.0
2016 $290.0 $250.0 $225.0 $200.0 $965.0
2015 $199.0 $197.0 $164.0 $126.0 $686.0
2014 $129.0 $128.0 $69.0 $65.0 $391.0
2013 $68.0 $69.0 $75.0 $66.0 $278.0
2012 $88.0 $-1.0 $-2.0 $-1.0 $84.0
2011 $-20.0 $0.0 $0.0 $-20.0
2010 $-28.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.